Cristian Molina Pizarr | Artificial Intelligence | Innovative Research Award

Published on by Cognitive Scientist Awards

Dr. Cristian Molina Pizarr | Artificial Intelligence | Innovative Research Award

Hospital Virgen de los Lirios Alcoi Alicante | Spain

Dr. Cristian Antonio Molina Pizarro is a distinguished psychiatrist recognized for his contributions to mental health, suicide prevention, and dual pathology research. Currently serving at Hospital Virgen de los Lirios, he integrates clinical expertise with innovative research to address complex psychiatric conditions. His career spans across Mexico, Spain, Chile, and the United States, where he has worked on pioneering initiatives in early psychosis management, addiction medicine, and artificial intelligence applications in psychiatry. He has served as Subdirector in the Mexican Ministry of Health, where he coordinated national suicide prevention and mental health support brigades. His extensive training in psychiatry, dual pathology, psychosomatics, and emergency mental health care reflects a deep commitment to patient-centered approaches and evidence-based practice. With publications in PubMed and Scopus, advisory roles in major pharmaceutical collaborations, and leadership in international programs, Dr. Molina Pizarro exemplifies innovation, clinical excellence, and global leadership in mental health advancement.

Profile

ORCID

Education

Dr. Molina Pizarro holds a medical degree from the University of Guadalajara, Mexico, and a degree in science from Universidad Federico Santa María, Chile. He specialized in psychiatry at Fundación Jiménez Díaz, Universidad Autónoma de Madrid, where he developed advanced expertise in psychotic disorders and dual pathology. His academic journey includes diverse and highly specialized training: an expert course in schizophrenia and depression from the Spanish Society of Dual Pathology, an emergency diploma in psychiatry from Universidad de Alcalá, and psychosomatics training at Instituto de Estudios Psicosomáticos y Psicoterapia Médica in Madrid. He also completed the University of Virginia Addiction Medicine Fellowship at the Center for Leading Edge Addiction Research. These multidisciplinary studies provided him with a comprehensive perspective on mental health, integrating biological, psychological, and social dimensions. His doctoral studies in medicine at Universidad Autónoma de Madrid further reinforce his academic foundation, preparing him for leadership in research and clinical innovation.

Experience

Dr. Molina Pizarro has extensive experience in clinical psychiatry, research, and public health leadership. He currently practices at Hospital Virgen de los Lirios and CSM La Fábrica Alcoy in Alicante, focusing on first-episode psychosis, relapse prevention, and dual diagnoses. Previously, he worked as a psychiatrist at Fundación Jiménez Díaz, Madrid, where he strengthened his expertise in complex psychiatric cases. As Subdirector in the Mexican Ministry of Health, he coordinated national suicide prevention initiatives, including the “Código 100” program, and led brigades for mental health support in vulnerable communities. His clinical practice emphasizes prevention, early intervention, and treatment adherence, particularly in schizophrenia, bipolar disorder, and substance use disorders. Internationally, he collaborates on digital health projects such as Memind, applying artificial intelligence to mental health detection and follow-up across Spain, USA, Mexico, and Chile. His career reflects a balance between high-level clinical practice, academic teaching, and leadership in national and international mental health programs.

Awards and Honors

Dr. Molina Pizarro has earned recognition for his innovative contributions to psychiatry, particularly in suicide prevention and dual pathology. As a senior speaker and advisory board member for pharmaceutical leaders including Janssen, Otsuka-Lundbeck, Rovi, and Lümbeck, he has influenced mental health strategies across Spain and Mexico. His leadership in the Mexican National Suicide Prevention Programme, “Código 100,” was highly commended for integrating clinical decision-making with human rights, gender equity, and interculturality in mental health services. Accredited as a teacher by the Community of Madrid’s Commission for Continuing Training in Health Professions, he has contributed significantly to psychiatry education and professional development. His published work in the British Medical Journal, PubMed, and Scopus-indexed journals adds further prestige to his profile. His patents in digital health innovation, specifically within AI-assisted psychiatric care, highlight his pioneering role in merging technology with clinical psychiatry. These achievements establish him as a forward-thinking leader in global mental health.

Research Focus

Dr. Molina Pizarro’s research bridges psychiatry, technology, and public health, with a central focus on suicide prevention, artificial intelligence applications, dual pathology, and substance use disorders. He has developed a digital ecosystem for suicide risk detection and management, integrating mobile applications and AI for population-level screening, follow-up, and relapse prevention. His ongoing projects emphasize dynamic models of suicidal risk and the integration of mental health within general health systems to reduce stigma and improve accessibility. His research also extends to first-episode psychosis, emphasizing early detection, treatment adherence, and relapse prevention in young populations. International collaborations, particularly the Memind project across Spain, USA, Mexico, and Chile, highlight his commitment to digital transformation in psychiatry. With publications in BMJ, PubMed, and Scopus, and advisory roles in pharmaceutical innovations, his research not only advances clinical practice but also contributes to systemic mental health reforms and innovative global strategies in psychiatric care.

Publications

Title: The Relation Between Violence and Suicidality in Mexico: The Impact of Different Types of Violence in Suicidal Behaviour Detected by a Massive Mental Health Screening App (MeMind)
Year: 2025

Conclusion

Dr. Cristian Antonio Molina Pizarro is an accomplished psychiatrist whose leadership in suicide prevention, dual pathology, and AI-driven mental health innovation, combined with international collaborations, clinical excellence, and impactful research, make him a strong candidate for the Innovative Research Award.

Korchia Theo | Psychiatry | Best Researcher Award

Published on by Cognitive Scientist Awards

Dr. Korchia Theo | Psychiatry | Best Researcher Award

Dr. Théo Korchia 🇫🇷 is a French psychiatrist specializing in early-onset schizophrenia 🧩, with a passion for innovation in mental health care 💡. Based at Aix-Marseille University and APHM 🏥, he completed a research fellowship at McGill University in Montreal 🇨🇦. His groundbreaking work emphasizes personalizing antipsychotic treatment using pharmacogenetics 🧬, improving patient adherence and quality of life ❤️. His notable contributions include addressing sexual dysfunction in schizophrenia treatment 💔, a topic often neglected. He published a major meta-analysis in JAMA Psychiatry 📘, shedding light on its prevalence. Winner of the Schizophrenia International Research Society award 🏆, Dr. Korchia advocates for a psychiatry that is humane, patient-centered, and scientifically rigorous 🔬. His work not only enhances clinical outcomes but also builds stronger therapeutic alliances through trust and transparency 🤝. Driven by compassion and innovation, he envisions a future where mental health care is personalized, inclusive, and profoundly impactful 🌍.

Profile

Education 🎓

Théo Korchia began his medical education in France 🎓, obtaining his degree in psychiatry with a focus on early-onset psychotic disorders 🧠. Supported by Aix-Marseille University and APHM 🏥, his academic journey was enriched by international exposure at McGill University 🇨🇦, where he deepened his expertise in psychiatric research and pharmacogenetics 🧬. His commitment to academic excellence led to extensive training in clinical practice, psychopharmacology, and patient-centered care 🩺. Throughout his studies, he explored the intersection of pharmacology, genetics, and psychiatry, aiming to personalize schizophrenia treatment for better efficacy and fewer side effects 🧪. His education was marked by a strong emphasis on translational research, ethics, and therapeutic alliance 🤝. Dr. Korchia continues to be involved in academic teaching and mentoring, sharing his knowledge with students and young professionals 📚. His education forms the bedrock of his mission: to evolve psychiatric care into a more compassionate, evidence-based, and individualized discipline 🌟.

Experience 👨‍🏫

Dr. Korchia’s clinical journey began in France 🇫🇷 at APHM and Aix-Marseille University 🏥, where he treated patients with early-onset schizophrenia and related psychotic disorders 🧠. His international experience includes a transformative year of research at McGill University 🇨🇦, focusing on pharmacogenetics and treatment personalization 🧬. In both hospital and research settings, he has contributed to improving psychiatric care through innovative approaches, especially regarding the management of antipsychotic side effects 🩻. With a hands-on approach, he integrates patient voices in treatment plans 🗣️, fostering therapeutic alliance and adherence 🤝. He has collaborated with multidisciplinary teams, presented findings at international conferences 🌐, and published in high-impact journals like JAMA Psychiatry 📘. Passionate about breaking stigmas, Dr. Korchia also advocates for the recognition of sexual dysfunction in psychiatric care 💔. His experience bridges cutting-edge science and compassionate care, making him a leading voice in progressive psychiatry 💡.

Awards & Recognitions 🏅

Dr. Théo Korchia was honored by the Schizophrenia International Research Society 🏆 for his pioneering research in early-onset schizophrenia treatment 🧠. He was supported by Aix-Marseille University and the Assistance Publique des Hôpitaux de Marseille 🎓🏥, which facilitated his international research fellowship at McGill University 🇨🇦. His impactful publication in JAMA Psychiatry 📘—a meta-analysis involving 21,000+ patients—highlighted sexual dysfunction prevalence in schizophrenia, earning him global recognition 🌍. His work addressing often-ignored dimensions of psychiatric care, such as sexual health 💔, has been lauded for its clinical relevance and humanistic perspective. Known for combining scientific rigor 🔬 with empathy ❤️, he is frequently invited to share insights at conferences and symposiums worldwide 🎤. These accolades reflect not only academic excellence but also his commitment to enhancing patient-centered care 🧩. Dr. Korchia’s recognition symbolizes a growing awareness of the holistic needs of individuals with mental illness 🌟.

Research Interests 🔬

Dr. Korchia’s research centers on early-onset schizophrenia 🧠, with a sharp focus on pharmacogenetics 🧬 to personalize antipsychotic treatments and minimize side effects. He addresses the often-overlooked issue of sexual dysfunction 💔 in schizophrenia, a side effect that significantly impacts quality of life and treatment adherence 📉. His landmark meta-analysis in JAMA Psychiatry 📘 quantified this burden, influencing clinical guidelines and public discourse. He explores how integrating patient perspectives and improving therapeutic alliances 🤝 can enhance outcomes. His work bridges biological psychiatry and patient-centered care 🩺, emphasizing that innovation is not just drug development, but rethinking care models to reflect human experience 🧠❤️. He champions the inclusion of sexual health in risk-benefit analysis of psychiatric medications 💡. Ultimately, Dr. Korchia’s goal is to evolve psychiatry into a more humane, personalized, and effective field—where each treatment plan respects the unique biology and lived experience of the individual 🌍.

Publications 

  • Impact of perceived side-effects of psychotropic treatments on quality of life in patients with severe mental illness

    Dialogues in Clinical Neuroscience
    2025-12-31 | Journal article
    DOI: 10.1080/19585969.2025.2463443
    CONTRIBUTORS: Théo Korchia; Mélanie Faugère; Vincent Achour; Eloïse Maakaron; Christelle Andrieu-Haller; Guillaume Fond; Christophe Lançon

  • Lifetime sexual violence experienced by women asylum seekers and refugees hosted in high-income countries: Literature review and meta-analysis

    Journal of Forensic and Legal Medicine
    2024-01 | Journal article
    DOI: 10.1016/j.jflm.2023.102622
    CONTRIBUTORS: Laura Cayreyre; Théo Korchia; Anderson Loundou; Maeva Jego; Didier Théry; Julie Berbis; Gaëtan Gentile; Pascal Auquier; Jérémy Khouani

  • Sexual Dysfunction in Schizophrenia

    JAMA Psychiatry
    2023-11-01 | Journal article
    DOI: 10.1001/jamapsychiatry.2023.2696
    Part ofISSN: 2168-622X
    CONTRIBUTORS: Théo Korchia; Vincent Achour; Mélanie Faugere; Ali Albeash; Dong Keon Yon; Laurent Boyer; Guillaume Fond

  • Utilizing pharmacogenetics when treating first episode psychosis

    Journal of Psychiatry and Neuroscience
    2023-01-03 | Journal article
    DOI: 10.1503/jpn.220154
    Part of ISSN: 1180-4882
    CONTRIBUTORS: Theo Korchia; Ridha Joober; Raphaelle Richieri; Priyadharshini Sabesan; Lena Palaniyappan